anidulafungin has been researched along with Obesity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aarnoutse, RE; Brüggemann, RJ; Burger, DM; Lempers, VJ; Muilwijk, EW; Pickkers, P; Warris, A | 1 |
| Azanza, JR; Montejo, M | 1 |
2 review(s) available for anidulafungin and Obesity
| Article | Year |
|---|---|
Impact of special patient populations on the pharmacokinetics of echinocandins.
Topics: Adolescent; Adult; Anidulafungin; Antifungal Agents; Candida; Caspofungin; Child; Critical Illness; Drug Interactions; Echinocandins; Hematologic Diseases; Humans; Infant, Newborn; Kidney; Lipopeptides; Liver; Micafungin; Microbial Sensitivity Tests; Obesity | 2015 |
[Pharmacokinetics and pharmacodynamics: interactions and adverse effects. Comparison with other echinocandins].
Topics: Aged; Anidulafungin; Antifungal Agents; Caspofungin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Monitoring; Echinocandins; Gastrointestinal Diseases; Half-Life; Humans; Immunosuppressive Agents; Lipopeptides; Liver; Liver Failure; Mycoses; Obesity; Renal Insufficiency; Tissue Distribution | 2008 |